Equity · Currency in GBp · Last updated Jun 6, 2026
Abingdon Health plc engages in the development, manufacture, and distribution of diagnostic devices worldwide. The company offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; PCRD and PCRD FLEX, nucleic acid lateral flow tests used for rapid readouts post isothermal amplification; Abingdon Simply Test, a range of self-tests; and 2019-nCoV Antigen Test, a rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2. It also provides AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. In addition, the company provides contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. Further, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health plc was incorporated in 2008 and is headquartered in York, the United Kingdom.
Looking to balance out your exposure to ABDX.L? The ETFs below have the lowest correlation with ABDX.L — they tend to move on their own, which can help reduce risk when ABDX.L drops. The stock ideas table highlights individual companies that behave independently from ABDX.L.
No Diversifiers Found for ABDX.L
We do not have enough correlation history to rank diversifiers for this symbol yet.
Diversification Analysis
Build a portfolio that complements ABDX.L
Add ABDX.L to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.